Skip to main content

Council Capital Closes Fourth Fund

Nashville, TN-based healthcare private equity firm Council Capital has closed its fourth fund, Council Capital IV (which includes Council Capital IV, L.P. and affiliated entities) at its hard cap of $200mn. Council Capital’s most recent fund, Council Capital III, began investing $149mn of total third party commitments in 2015.

Council Capital IV will continue the firm’s focus on investing in lower middle market healthcare services and healthcare information technology companies that it believes are focused on the right side of change in healthcare, are well-positioned for rapid growth, and fit within the firm’s focused set of targeted healthcare sub-sectors.

Grant Jackson, Managing General Partner at Council Capital, said, “We are excited about the successful closing of Council Capital IV and humbled by the interest received from investors. Our goal is to ensure that every investment we make delivers value for our investors as well as our portfolio company teams and the customers they serve. We are excited to continue building our portfolio of companies on the right side of change in healthcare – which we categorize as companies making contributions to improve the healthcare system and accelerating the shift from volume of service to the delivered value of service. We greatly appreciate that our investors have entrusted us to execute the Council Model with their capital.”

Recent investments made by Council Capital include Advanced Care Partners, a provider of in-home nursing to medically fragile populations (primarily children);  NeurAbilities, a provider of integrated behavioral and medical health services to children with autism and special needs; Physician Housecalls, a provider of geriatric primary care services via home visitation and telemedicine; Savida Health, a provider of outpatient addiction treatment services, and WCCC, a software company focused on developing an end-to-end cost containment solution.

© The Sortino Group Ltd

All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or scanning or otherwise, except under the terms of the Copyright, Designs and Patents Act 1988 or under the terms of a licence issued by the Copyright Licensing Agency or other Reprographic Rights Organisation, without the written permission of the publisher. For more information about reprints from AlphaWeek, click here.